Evolving Concepts in Pathogenesis and Treatment of ANCA-associated Systemic Vasculitides
Cees G. M. Kallenberg,Minghui Zhao
DOI: https://doi.org/10.1111/j.1440-1797.2009.01093.x
2009-01-01
Nephrology
Abstract:The anti-neutrophil cytoplasmic auto-antibody (ANCA)-associated systemic vasculitides (ASV) comprise Wegener's Granulomatosis (WG), microscopic polyangiitis (MPA), including its renal limited form (idiopathic necrotizing and crescentic glomerulonephritis), and Churg–Strauss syndrome.1 The discovery of ANCA, directed either to proteinase 3 (PR3) or myeloperoxidase (MPO) in these conditions, has given an enormous stimulant to further studies into the pathogenesis of ASV and contributed to the development of new therapeutic approaches in these serious diseases. PR3-ANCA and MPO-ANCA, in the right clinical context, are both sensitive and specific for WG and MPA, and titers of PR3-ANCA follow disease activity of WG to some extent.2 These clinical observations suggest that the auto-antibodies are involved in the pathogenesis of their associated diseases. Indeed, many in vitro and in vivo experimental data support a pathogenetic role for ANCA in ASV. This relates particularly to MPO-ANCA as a pathogenic factor in MPA. The occurrence of transient neonatal small-vessel vasculitis in a child born from a mother with MPO-ANCA vasculitis is an experiment of nature proving the pathogenic potential of MPO-ANCA that induced, via placental transfer of IgG-class auto-antibodies, vasculitic lesions in the foetus.3 Also, experimentally, Xiao et al. have shown that anti-MPO antibodies can induce small-vessel vasculitis.4 By immunizing MPO-deficient mice with murine MPO, an MPO-directed immune response occurred in these animals. When their splenocytes or even their IgG-class antibodies were transferred into recipient normal mice, these latter mice developed necrotizing and crescentic glomerulonephritis with pulmonary capillaritis (transfer of splenocytes) or pauci-immune focal glomerulonephritis (IgG transfer), all hallmarks of MPA. In this issue of the journal, van Timmeren et al. further elaborate on the mechanisms involved in MPO-ANCA-associated systemic vasculitis.5 They provide evidence that the complement system plays a major role in lesional development. As immunoglobulin depositions are generally absent from the lesions, which are, therefore, designated as pauci-immune, activation of the complement system via the classical pathway seems unlikely. Indeed, the authors describe that the complement system is activated via the alternative pathway. Lesions did not develop in the experimental model for MPO-ANCA-associated vasculitis when MPO antibodies were transferred into recipient mice that were deficient for complement factor B or C5.6 This might open the way for therapeutic use of either antibodies to C5a or to the C5a receptor. How the alternative pathway of complement is activated is currently not known. It has been known for a long time that neutrophils are important effector cells in ASV. Depletion of neutrophils prevents the development of lesions in the experimental model of MPO-ANCA-associated vasculitis.7 Interaction of neutrophils with the endothelium is crucial in the pathophysiology of ASV. The interplay between neutrophils, endothelial cells and ANCA is discussed in this issue by Pankhurst et al.8 Better insight into this process will allow the development of more specific therapeutic approaches. Besides ANCA, other auto-antibodies could as well play a role in the pathogenic events leading to small-vessel vasculitis. Endothelial cell antibodies (ACA) have been detected in various systemic autoimmune diseases and vasculitides.9 These ACA could directly target the endothelial layer at the inside of blood vessels. Their antigenic specificities are, however, not clear in many conditions, and their pathogenetic potential not yet elucidated. ACA are generally detected with human umbilical vein endothelial cells as a substrate. Using this substrate, it is questionable whether all ACA, particularly those directed against organ-specific endothelial cell antigens, can be detected. In this issue, Hu et al. describe the presence of ACA using glomerular endothelial cells as a substrate in sera from patients with ASV and compare the results with those obtained using human umbilical vein endothelial cells as a substrate.10 Whereas in vivo experimental data underscore a pathogenic role for MPO-ANCA in ASV, the pathogenic role of PR3-ANCA is less clear.1 PR3-ANCA are, at least in a Caucasian population, strongly associated with granulomatous vasculitis as seen in WG.11 The presence of granulomatous inflammation suggests involvement of cell-mediated immunity in the disease process. Indeed, activated T cells have been detected in the peripheral blood of patients with AAV, even during quiescent disease.12 The role of T cells in the pathogenesis of WG is further discussed in this issue by Abdulahad et al.13 Although the pathogenetic pathways leading to necrotizing vasculitis and granuloma formation have largely been clarified, the aetiology of ASV has still not been fully elucidated. Both genetic and exogenous factors have been incriminated. With respect to exogenous factors, microbial agents have been suggested to be involved, both in disease induction and re-activation.14 Besides micro-organisms, drugs play a role in the induction of, particularly, MPO-ANCA, leading, in a subset of patients, to the clinical expression of ASV. In this issue, Gao and Zhao discuss drug-induced ASV as a particular subset of this group of diseases.15 ASV are serious diseases with an extremely high mortality rate when left untreated. Treatment, classically, consists of immunosuppressives, in particular cyclophosphamide, in combination with corticosteroids.16 Although reasonably effective, this regimen is associated with significant side-effects without preventing the occurrence of relapses.16 So, more effective and less toxic therapeutic approaches are clearly wanted. Jayne, in a final contribution, discusses randomized controlled studies that have changed the classical approach with cyclophosphamide and corticosteroids.17 They also review new treatment modalities, including biologicals, which are currently in development for ASV. In summary, this issue of Nephrology gives an overview of current developments in the aetiopathogenesis and treatment of ASV. Insight into pathogenetic pathways allowing more targeted treatment will hopefully lead to better prospects for patients with these life-threatening diseases.